Volume 70, Issue 5 pp. 722-733

Original Article

Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma

Aya Shinozaki-Ushiku,

Aya Shinozaki-Ushiku

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Tetsuo Ushiku,

Tetsuo Ushiku

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Shigeki Morita,

Shigeki Morita

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Masaki Anraku,

Masaki Anraku

Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Jun Nakajima,

Jun Nakajima

Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Masashi Fukayama,

Corresponding Author

Masashi Fukayama

[email protected]

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Address for correspondence: M Fukayama, Department of Pathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. e-mail: [email protected]Search for more papers by this author

Aya Shinozaki-Ushiku,

Aya Shinozaki-Ushiku

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Tetsuo Ushiku,

Tetsuo Ushiku

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Shigeki Morita,

Shigeki Morita

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Masaki Anraku,

Masaki Anraku

Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Jun Nakajima,

Jun Nakajima

Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Search for more papers by this author

Masashi Fukayama,

Corresponding Author

Masashi Fukayama

[email protected]

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

First published: 11 November 2016

https://doi.org/10.1111/his.13123

Citations: 65

Share a link

Email
Wechat
Bluesky

Abstract

Aims

Malignant mesothelioma is a highly aggressive cancer that is usually diagnosed at advanced stages; thus, highly sensitive and specific markers are necessary for its early definitive diagnosis. The aim of this study was to evaluate the diagnostic utility and prognostic significance of BAP1 and EZH2 in malignant mesothelioma.

Methods and results

The expression of BAP1 and EZH2 was investigated by immunohistochemistry in 32 malignant mesotheliomas and 44 benign mesothelial proliferative lesions, including well-differentiated papillary mesothelioma (n = 4), mesothelial inclusion cyst (n = 22), and reactive mesothelial hyperplasia (n = 18). BAP1 loss and high EZH2 expression were observed in 17 (53%) and 22 (66%) malignant mesothelioma cases, respectively, whereas none of the benign lesions showed BAP1 loss or high EZH2 expression. The combination of BAP1 loss and high EZH2 expression as markers to differentiate epithelioid/biphasic malignant mesothelioma from benign mesothelial lesions was highly sensitive (90%) and specific (100%). There were no statistically significant associations between parameters such as age and sex of patients, tumour location, asbestos exposure, treatment, histology, and BAP1 or EZH2 expression. Survival analysis revealed that BAP1 loss, but not high EZH2 expression, was associated with a better prognosis.

Conclusions

BAP1 loss and high EZH2 expression were highly specific to malignant mesothelioma in differentiating it from benign mesothelial proliferations, and the combination of these two markers improved the diagnostic accuracy.

References

1Churg A, Sheffield BS, Galateau-Salle F. New markers for separating benign from malignant mesothelial proliferations: are we there yet? Arch. Pathol. Lab. Med. 2016; 140; 318–321.
10.5858/arpa.2015-0240-SA
CAS PubMed Web of Science® Google Scholar
2Husain AN, Colby TV, Ordonez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch. Pathol. Lab. Med. 2009; 133; 1317–1331.
10.5858/133.8.1317
PubMed Web of Science® Google Scholar
3Minato H, Kurose N, Fukushima M et al. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am. J. Clin. Pathol. 2014; 141; 85–93.
10.1309/AJCP5KNL7QTELLYI
PubMed Web of Science® Google Scholar
4Sheffield BS, Hwang HC, Lee AF et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am. J. Surg. Pathol. 2015; 39; 977–982.
10.1097/PAS.0000000000000394
PubMed Web of Science® Google Scholar
5Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 2011; 43; 1022–1025.
10.1038/ng.912
CAS PubMed Web of Science® Google Scholar
6Bott M, Brevet M, Taylor BS et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 2011; 43; 668–672.
10.1038/ng.855
CAS PubMed Web of Science® Google Scholar
7McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum. Pathol. 2015; 46; 1670–1678.
10.1016/j.humpath.2015.06.024
CAS PubMed Web of Science® Google Scholar
8Andrici J, Sheen A, Sioson L et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod. Pathol. 2015; 28; 1360–1368.
10.1038/modpathol.2015.87
CAS PubMed Web of Science® Google Scholar
9Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN, Marchevsky AM. BAP1 immunostain and CDKN2A (p16) FISH analysis: clinical applicability for the diagnosis of malignant mesothelioma in effusions. Diagn. Cytopathol. 2016; 44; 599–606.
10.1002/dc.23491
PubMed Web of Science® Google Scholar
10Singhi AD, Krasinskas AM, Choudry HA et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod. Pathol. 2016; 29; 14–24.
10.1038/modpathol.2015.121
CAS PubMed Web of Science® Google Scholar
11Hwang HC, Pyott S, Rodriguez S et al. BAP1 immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas. Am. J. Surg. Pathol. 2016; 40; 714–718.
10.1097/PAS.0000000000000616
PubMed Web of Science® Google Scholar
12Hwang HC, Sheffield BS, Rodriguez S et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am. J. Surg. Pathol. 2016; 40; 120–126.
10.1097/PAS.0000000000000529
PubMed Web of Science® Google Scholar
13Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol. Oncol. Res. 2014; 20; 145–151.
10.1007/s12253-013-9677-2
CAS PubMed Web of Science® Google Scholar
14Cigognetti M, Lonardi S, Fisogni S et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod. Pathol. 2015; 28; 1043–1057.
10.1038/modpathol.2015.65
CAS PubMed Web of Science® Google Scholar
15Nasu M, Emi M, Pastorino S et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol. 2015; 10; 565–576.
10.1097/JTO.0000000000000471
CAS PubMed Web of Science® Google Scholar
16Farzin M, Toon CW, Clarkson A et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 2015; 47; 302–307.
10.1097/PAT.0000000000000250
CAS PubMed Web of Science® Google Scholar
17LaFave LM, Beguelin W, Koche R et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 2015; 21; 1344–1349.
10.1038/nm.3947
CAS PubMed Web of Science® Google Scholar
18Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat. Med. 2016; 22; 128–134.
10.1038/nm.4036
CAS PubMed Web of Science® Google Scholar
19Chung CT, Santos Gda C, Hwang DM et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J. Clin. Pathol. 2010; 63; 630–634.
10.1136/jcp.2010.076794
PubMed Web of Science® Google Scholar
20Wu D, Hiroshima K, Matsumoto S et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am. J. Clin. Pathol. 2013; 139; 39–46.
10.1309/AJCPT94JVWIHBKRD
CAS PubMed Web of Science® Google Scholar
21Andrici J, Jung J, Sheen A et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum. Pathol. 2016; 51; 9–15.
10.1016/j.humpath.2015.12.012
CAS PubMed Web of Science® Google Scholar
22Andrici J, Parkhill TR, Jung J et al. Loss of expression of BAP1 is very rare in non-small cell lung carcinoma. Pathology 2016; 48; 336–340.
10.1016/j.pathol.2016.03.005
CAS PubMed Web of Science® Google Scholar
23Murai F, Koinuma D, Shinozaki-Ushiku A, Fukayama M, Miyaozono K, Ehata S. EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway. Cell Discov. 2015; 1; 15026.
10.1038/celldisc.2015.26
PubMed Web of Science® Google Scholar
24Bueno R, Stawiski EW, Goldstein LD et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 2016; 48; 407–416.
10.1038/ng.3520
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume70, Issue5

April 2017

Pages 722-733

Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma

Abstract

Aims

Methods and results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma

Abstract

Aims

Methods and results

Conclusions

References

Citing Literature

References

Related

Information